Overview

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
OSI Pharmaceuticals
Treatments:
Lurtotecan
Topotecan